Persistent intracerebral hemorrhage (ICH) is a major cause of death and disability after traumatic brain injury (TBI) for which no medical treatment is available. Delayed bleeding is often ascribed to consumptive coagulopathy initiated by exposed brain tissue factor. We examined an alternative hypothesis, namely, that marked release of tissue-type plasminogen activator (tPA) followed by delayed synthesis and release of urokinase plasminogen activator (uPA) from injured brain leads to posttraumatic bleeding by causing premature clot lysis. Using a murine model of severe TBI, we found that ICH is reduced in tPA(-/-) and uPA(-/-) mice but increased in PAI-1(-/-) mice compared with wild-type (WT) mice. tPA(-/-), but not uPA(-/-), mice developed a systemic coagulopathy post-TBI. Tranexamic acid inhibited ICH expansion in uPA(-/-)mice but not in tPA(-/-) mice. Catalytically inactive tPA-S(481)A inhibited plasminogen activation by tPA and uPA, attenuated ICH, lowered plasma d-dimers, lessened thrombocytopenia, and improved neurologic outcome in WT, tPA(-/-), and uPA(-/-) mice. ICH expansion was also inhibited by tPA-S(481)A in WT mice anticoagulated with warfarin. These data demonstrate that protracted endogenous fibrinolysis induced by TBI is primarily responsible for persistent ICH and post-TBI coagulopathy in this model and offer a novel approach to interrupt bleeding.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400292PMC
http://dx.doi.org/10.1182/blood-2014-08-588442DOI Listing

Publication Analysis

Top Keywords

tpa-/- upa-/-
12
upa-/- mice
12
intracerebral hemorrhage
8
traumatic brain
8
brain injury
8
mice
8
plasminogen activator
8
ich expansion
8
ich
6
endogenous plasminogen
4

Similar Publications

Novel Deep Sea Isoindole Alkaloid FGFC1 Exhibits Its Fibrinolytic Effects by Inhibiting Thrombin-Activatable Fibrinolysis Inhibitor.

Pharmaceuticals (Basel)

October 2024

Department of Marine Bio-Pharmacology, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.

Background: The thrombin-activatable fibrinolysis inhibitor (TAFI) is an important regulator in the balance between blood clot formation (coagulation) and dissolution (fibrinolysis), which is mainly activated by thrombin bonded with thrombomodulin (TM).

Methods: In this study, the investigation focused on the unique target TAFI of fungi fibrinolytic compound 1 (FGFC1), a novel fibrinolytic compound sourced from the deep sea. In this sense, the regulation of TAFI by FGFC1, in comparison to established TAFI inhibitors such as DS-1040 and PCTI in hPPP, was investigated, which was validated through the molecular docking of FGFC1 to TAFI.

View Article and Find Full Text PDF

While members of large paralogous protein families share structural features, their functional niches often diverge significantly. Serine protease inhibitors (SERPINs), whose members typically function as covalent inhibitors of serine proteases, are one such family. Plasminogen activator inhibitor-1 (PAI-1) is a prototypic SERPIN, which canonically inhibits tissue-and urokinase-type plasminogen activators (tPA and uPA) to regulate fibrinolysis.

View Article and Find Full Text PDF

Orchestra of ligand-activated transcription factors in the molecular symphony of SERPINE 1 / PAI-1 gene regulation.

Biochimie

January 2025

Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic. Electronic address:

Plasminogen activator inhibitor 1 (PAI-1) is a crucial serine protease inhibitor that prevents plasminogen activation by inhibiting tissue- and urokinase-type plasminogen activators (tPA, uPA). PAI-1 is well-known for its role in modulating hemocoagulation or extracellular matrix formation by inhibiting plasmin or matrix metalloproteinases, respectively. PAI-1 is induced by pro-inflammatory cytokines across various tissues, yet its regulation by ligand-activated transcription factors is partly disregarded.

View Article and Find Full Text PDF
Article Synopsis
  • Fibrinolysis is the process of breaking down fibrin in blood clots, initiated by plasminogen activation through tPA and uPA, while antifibrinolytics like PAI-1 and αAP help regulate this process.
  • Rare inherited disorders of the fibrinolytic pathway often lead to excessive bleeding, with conditions such as PAI-1 deficiency being treated with antifibrinolytic medications like aminocaproic acid during surgeries.
  • Diagnosing these disorders is challenging, often requiring specialized testing for protein activity and genetic mutations, as routine tests typically lack specificity and sensitivity for such conditions.
View Article and Find Full Text PDF
Article Synopsis
  • Enolase is an important enzyme in our bodies that helps convert energy during processes like glycolysis and gluconeogenesis.
  • Some types of parasites and bacteria have a special kind of enolase that helps them stick to host tissues, making it easier for them to cause infections.
  • Researchers are studying enolase from the Fasciola hepatica parasite, which could help us understand how it invades its host and possibly lead to better treatments for the diseases it causes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!